In mid-November, Pfizer appointed Chris Boshoff as chief scientific officer, taking over for Mikael Dolsten, who announced his departure in July. Boshoff is currently Pfizer”s chief oncology officer. But the appointment is likely to do little to satisfy Starboard, said Jeff Jonas, of Gabelli Funds.
